



## VERIFICATION OF TRANSLATION

I, Derek JARVIS, hereby declare that I am conversant with the French and English languages and certify that to the best of my knowledge and belief the following is a true translation of the text of the French patent No. PCT/FR02/00088

Signature:

Derek Jarvis

Derek JARVIS  
7, rue d'Upsal  
67000 Strasbourg

21<sup>st</sup> July 2003.



1

## PROCESS FOR THE MATURATION OF DENDRITIC CELLS AND FOR THE ACTIVATION OF MACROPHAGES WITH RU 41740

4

5

### 6 DESCRIPTION

7

8 The present invention is situated in the field of cell therapy. It relates to a process  
9 capable of generating mature dendritic cells and/or activated mammalian  
10 macrophages starting from monocytes, monocyte precursors or hematopoietic stem  
11 cells.

12

13 The dendritic cells play a critical role in the emergence of the anti-tumor, anti-  
14 infectious and auto-immune immune response. In fact, the dendritic cells are the only  
15 cells capable of inducing a primary response from the T lymphocytes. They thus  
16 have a key role in the initiation of the immune response. Such a function is related to  
17 the many morphological properties and surface molecules of the dendritic cells. In  
18 fact, owing to extensive increases in size of their cytoplasmic membrane, the  
19 dendritic cells have a particularly large contact surface with their environment.  
20 Furthermore, they possess at their surface very many histocompatibility antigens of  
21 class I and class II which makes antigen presentation possible.

22

23 After being taken up by the dendritic cell, the antigen undergoes "processing" before  
24 being presented to the T lymphocyte. The re-organization which requires an active  
25 cell metabolism comprises four steps: the capture of the antigen, its enzymatic  
26 degradation to small peptide fragments in an intracellular compartment, the  
27 association of these fragments with the class II molecules of the MHC and the  
28 migration of the peptides-class II molecules complexes to the surface of the antigen  
29 presenting cell (APC) for presentation to the T cell receptor (TcR) of the helper T  
30 lymphocyte (Th). The first step (capture), which is temperature-independent, is  
31 performed through the intermediary of non-specific receptors or as a result of other  
32 mechanisms still poorly understood. The larger the molecules, the more easily they  
33 are captured. The second step, which is temperature-dependent (it is blocked at 4

1 degrees), is the ingivitis\_tion of the antigen in the phagosomes which then fuse with  
2 the lysosomes (intracytoplasmic organelles rich in proteases), thus giving rise to the  
3 endosomes at acid pH. The proteolysis of the antigen into peptide fragments occurs  
4 in these vesicles as a result of the action in particular of cathepsin B, then D. This  
5 step can be blocked by ammonium ions which inhibit the phagosome-lysosome  
6 linkage, or by chloroquine which raises the pH of the lysosomes. The third step is a  
7 complex process still poorly understood in detail, which results in the association  
8 between the class II molecule of the MHC and some specific fragments of the  
9 degraded antigen usually constituted of nine to twenty five amino acids. The fourth  
10 step involves the migration of the class II molecule—peptide complex (called C3  
11 form) to the surface of the APC. The complex thus formed can then interact with the  
12 appropriate TcR at the surface of the Th lymphocyte provided that the molecules of  
13 the major histocompatibility complex (MHC) of the lymphocyte belong to the same  
14 haplotype as those of the presenting cell (allogenic restriction).

15

16 The dendritic cells are moreover very rich in co-stimulatory molecules of the immune  
17 response, such as the molecules CD80, CD86, CD40 which activate the molecules  
18 CD28, CTLA-4 and CD40L of the T lymphocytes, respectively, by initiating the  
19 immune response. They also possess very many adhesion molecules, like the  
20 molecule CD54 or the molecule CD11a/CD18, and this facilitates the co-operation  
21 between the dendritic cells and the T cells. Another special characteristic of the  
22 dendritic cells is to deploy different functions depending on their stage of  
23 differentiation. Thus, the capture of the antigen and its transformation are the two  
24 principal functions of the immature dendritic cell, whereas its capacities to present  
25 the antigen in order to stimulate the T cells increase as the dendritic cells migrate  
26 into the tissues and the lymphatic ganglia. This change of functionality corresponds  
27 to a maturation of the dendritic cell. Thus, the passage of the immature dendritic cell  
28 to the mature dendritic cell represents a fundamental step in the initiation of the  
29 immune response. This maturation can be easily followed owing to the change of the  
30 surface markers during this process. The surface markers characteristic of the  
31 different stages of maturation of the dendritic cells are summarized in the Table  
32 below.

33

Cell type	Surface markers
Monocytes	CD14++, DR+, CD86+, CD16+/-, CD54+, CD40+
Immature dendritic cell	CD14-, CD16-, CD80+/-, CD83-, CD86+, CD1a+, CD54+, DQ+, DR++
Mature dendritic cell	CD14-, CD83++, CD86++, CD80++, DR+++, DQ++, CD40++, CD54++, CD1a-

1  
2 **Table 1**  
3

4 The isolation of the dendritic cells from peripheral blood is very difficult because less  
5 than 1% of the white blood cells belong to this category. In the same way, the  
6 extraction from the tissues is impossible in man and very complicated in animals.

7 That is why an important advance was made when it became possible to generate  
8 dendritic cells from hematopoietic precursors and monocytes in the presence of  
9 different cytokines. Immature dendritic cells can be produced from monocytes in the  
10 presence of GM-CSF and IL-4 and the immature dendritic cells obtained will mature  
11 after contact with the TNF- $\alpha$  or with other agents such as the CD40 ligand, the LPS  
12 or media conditioned with macrophages. These last agents are complex or toxic  
13 substances. Similarly, the activation of the macrophages *in vivo* is complicated and  
14 difficult to control. That is why the activation *ex vivo* represents an appropriate  
15 means for experimental studies and therapeutic applications.

16  
17 The activated macrophages are cells that are encountered in the tissues after a  
18 process of inflammatory activation by specific or non-specific inducers. These cells  
19 are involved in the removal of toxic or pathogenic agents or cancerous or degenerate  
20 cells.

21  
22 RU 41740, sold under the trade name Biostim by the Cassenne Laboratories  
23 (France), is a medicine composed of glycoprotein extracts obtained from a strain of  
24 *Klebsiella pneumoniae* K<sub>2</sub>O<sub>1</sub> (strain O1K2 NCTC 5055). It is obtained after lysis of  
25 the bacterial cell walls, organic extraction, centrifugation and ultrafiltration.

26  
27 It is composed of: - 80% of glycoproteins

c) amino acids, lipids and nucleic acids.

The glycoprotein part is divided into 3 fractions: P1, F1, F2.

P1, of capsular origin, represents about 50% of RU 41740 and has a mean molecular weight of 95 kD.

F1 is of membrane origin and represents about 20% of RU 41740 and has a mean molecular weight of 350 kD.

F2 seems to be a part of P1.

RU 41740 does not cause a pyrogenic effect as is demonstrated by the negative Limulus test performed with this compound.

The present invention describes a novel procedure for the maturation of the dendritic cells by using as inducing agent of this maturation, RU 41740 or an analogue of this latter as defined below.

Of the agents making possible the maturation of the dendritic cells, the TNF- $\alpha$  is the one whose activity has been best characterized. Unfortunately, this lymphokine is very toxic and can trigger extremely violent responses *in vivo*, and this presents a major obstacle to its use in cell therapy. The LPS is another compound capable of inducing the maturation of the dendritic cells. It also exhibits great toxicity and induces a powerful pyrogenic effect, which is demonstrated by a positive Limulus test carried out with the LPS. It produces in addition variable results depending on the batch used. Finally, the LPS possesses the disadvantage of being degraded very rapidly. As regards the ligand of CD40 (CD40L), it directs the differentiation of the dendritic cells in a variable manner depending on the concentration and the time of incubation, and this makes it difficult to use in cell therapy.

As illustrated in the experimental examples below, RU 41740 makes it possible to induce the maturation of the dendritic cells with an efficacy similar to or better than the reference agents cited above. In addition it possesses several significant

1 advantages compared with these agents. In particular, RU 41740, sold under the  
2 trade name Biostim, has been used since 1982 as a medicine to stimulate the  
3 immune system during chronic infections (chronic bronchitis, otitis, rhinitis, ....), in a  
4 curative or preventive capacity. Its perfect tolerance by the organism has been  
5 demonstrated. Furthermore, RU 41740 is an extremely stable compound and the  
6 inventors have shown that it induces the maturation of the dendritic cells in a very  
7 reproducible and dose-dependent manner.

8

9 In a perspective of cell therapy requiring mature dendritic cells, RU 41740 is thus  
10 particularly valuable, owing to its lack of toxicity and simplicity of use in association  
11 with its stability and the reproducibility of the results obtained.

12

13 The use of any analogue of RU 41740 exhibiting similar properties to the latter in  
14 processes such as those described below, is obviously included in the framework of  
15 the present invention. In what follows, a compound comprising 60 to 90% of  
16 glycoproteins, and capable of inducing a significant increase of the expression of the  
17 molecules CD40, CD83, CD86 and HLA-DR and a very considerable diminution of  
18 the expression of the molecules CD14 and CD1a by the said dendritic cells when  
19 placed in contact with immature dendritic cells at concentrations less than or equal to  
20 1 mg/ml will be called an "RU 41740 analogue". Examples of RU 41740 analogues  
21 are LCOS 1013 and LCOS 1014, the processes for the production of which are  
22 described in Example 10. In the remainder of the text, unless otherwise indicated,  
23 the term "RU 41740" will designate both RU 41740 itself, constituting the active  
24 principle of Biostim, and an analogue of the latter.

25

26 A "RU 41740 analogue" is defined here as a compound consisting of glycoprotein  
27 extracts obtained from a *Klebsiella* strain (for example, the strain O<sub>1</sub>K<sub>2</sub>NC TC 5055  
28 of *Klebsiella pneumoniae*) as a result of at least the following steps:

- 29 • culture of the strain  
30 • lysis of the bacterial cell walls  
31 • organic extraction  
32 • centrifugation  
33 • ultrafiltration

1     • drying

2     Example 10 below presents two processes for the production of RU 41740

3     analogues, designated under the references LCOS 1013 and LCOS 1014.

4     The chemical structure of a RU 41740 analogue is composed mainly of

5     • carbohydrates = 70% ±12

6     • protein = 20% ± 6

7

8     Lipids, nucleosides and amino acids are present in trace amounts.

9     RU 41470 or an analogue of the latter possesses undetectable levels of bacterial

10    endotoxins (below 10 pg/ml).

11    RU 41470 is active in all of the processes using monocytes, precursors of the

12    monocytes or hematopoietic stem cells in man and animals. Furthermore, RU 41740

13    makes it possible to obtain at the same time activated macrophages from the same

14    starting cells.

15

16    The maturation of the dendritic cells as a result of placing them in the presence of

17    RU 41740 can be demonstrated by their phenotypic properties or by their functional

18    properties.

19

20    Thus, the invention relates to a process for obtaining mature dendritic cells

21    (Monocyte DendriticCells, or MODC) or activated macrophages, starting from

22    monocytes, monocyte precursors or hematopoietic stem cells, characterized in that

23    the said monocytes, monocyte precursors or stem cells are placed in contact with

24    RU 41740 or analogue of the latter, this compound being selected such that the

25    placing in contact of immature dendritic cells with the said compound makes possible

26    the functional maturation of the dendritic cells, as demonstrated by their capacity to:

27       c) trigger *in vitro* a primary response against an infectious or tumor antigen

28           placed in contact with the dendritic cells beforehand and/or during their culture

29           with the T lymphocytes;

30       c) induce the proliferation of T lymphocytes in a mixed autologous or allogenic

31           culture

32    Examples 6, 7, 9, 11 and 12 are illustrations of this process.

1 The invention also relates to a process for obtaining mature dendritic cells or  
2 activated macrophages starting from monocytes, monocyte precursors or  
3 hematopoietic stem cells, characterized in that the said monocytes, monocyte  
4 precursors or stem cells are placed in contact with RU 41740 or an analogue of this  
5 latter, this compound being selected such that the placing in contact of immature  
6 dendritic cells with the said compound makes possible the phenotypic maturation of  
7 the dendritic cells, demonstrated by a significant increase in the expression of the  
8 molecules CD40, CD83, CD86 and HLA-DR and a considerable diminution of the  
9 expression of the molecules CD14 and CD1a by the said dendritic cells.

10  
11 Examples 1 to 3 are illustrations of this process.

12  
13 Moreover, the natural physico-chemical properties of RU 41740 make it possible to  
14 adsorb molecules to them, in particular antigenic molecules. Hence this makes it  
15 possible to carry out in a simple manner a non-covalent coupling between RU 41740  
16 and antigenic molecules. It will then be possible to obtain mature dendritic cells  
17 specific for the antigens adsorbed to RU 41740 or an analogue of the latter by  
18 incubating immature dendritic cells with a coupling product formed between RU  
19 41740 or its analogue and the antigenic molecules selected. The coupling between  
20 RU 41740 or an analogue of the latter and the antigenic molecules can be carried  
21 out by any procedure known to the specialist skilled in the art. In a preferred manner,  
22 the antigens will be adsorbed to the surface of RU 41740 or its analogue, but other  
23 means of coupling (covalent linkage, affinity, etc....) can also be envisaged. The  
24 simplest coupling procedure, by adsorption to the surface of RU 41740 also  
25 possesses the advantage of making possible a coupling with essentially non-protein  
26 antigenic molecules.

27  
28 The product of coupling between RU 41740 or an analogue of the latter and  
29 antigenic molecules in order to induce the maturation of dendritic cells or the  
30 activation of macrophages forms part of the present invention. In a preferred  
31 embodiment of the coupling products of the invention, the coupling is assured by a  
32 non-covalent linkage. A particular coupling product is that of RU 41740 or an  
33 analogue of the latter with an essentially non-protein antigenic molecule.

34

1 The invention also relates to a process for obtaining mature dendritic cells presenting  
2 selected antigens, starting from monocytes, monocyte precursors or hematopoietic  
3 stem cells, characterized in that the said monocytes, monocyte precursors or stem  
4 cells are placed in contact with RU 41740 or an analogue of the latter, coupled to  
5 molecules comprising the said antigens.

6

7 In a preferred embodiment of the invention, the processes described above make it  
8 possible to obtain mature dendritic cells or activated macrophages by placing  
9 monocytes, monocyte precursors or hematopoietic stem cells in contact with RU  
10 41740, coupled or not to antigenic molecules.

11 In a preferred embodiment of the processes of the invention, RU 41740 is added to  
12 the culture medium of the cells at a final concentration included between 1 ng/ml and  
13 1 mg/ml, and preferentially between 100 ng/ml and 10 µg/ml.

14 In another preferred embodiment of the procedures of the invention, the monocytes,  
15 monocyte precursors or stem cells are placed in contact with an analogue of RU  
16 41740 obtained from the strain O<sub>1</sub>K<sub>2</sub> NCTC 5055 of *Klebsiella pneumoniae*. Such an  
17 analogue is for example LCOS 1013 or LCOS 1014, which is added to the culture  
18 medium of the cells at a final concentration preferably included between 1 ng/ml and  
19 1 mg/ml and, in an even more preferred manner, between 100 ng/ml and 50 µg/ml.

20 In the processes of the invention, the time of incubation of the monocytes, monocyte  
21 precursors or hematopoietic stem cells in the presence of RU 41740 or an analogue  
22 of the latter is preferentially from 1 to 15 days.

23

24 Cell therapy is a recent approach which consists of administering to a patient cells  
25 modified ex vivo so as to confer on them properties likely to be beneficial for the  
26 patient. The natural properties of the dendritic cells make them an excellent  
27 candidate for approaches to cell therapy in several fields of pathology, owing to their  
28 capacity to induce a primary immune response from the T lymphocytes. In particular,  
29 anti-tumor immunotherapy by administration of dendritic cells presenting one or more  
30 tumor antigens is a particularly promising cell therapy approach. The principle of this  
31 approach is to present to the immune system tumor antigens in a particularly  
32 efficacious manner in order to stimulate a response against the cells presenting the  
33 antigens. This approach is illustrated in Example 6 below.

1  
2 Example 7 presented below demonstrates that the administration of dendritic cells  
3 presenting antigens of micro-organisms makes it possible to obtain a primary  
4 immunization against these micro-organisms and can hence be used to combat  
5 infection.

6  
7 Another cell therapy approach using dendritic cells consists of directing the dendritic  
8 cells to express a tolerance reaction of the host towards particular antigens. This can  
9 be useful for example in order to induce a tolerance towards alloantigens at the time  
10 of an allogenic graft, to autoantigens at the time of an autoimmune disease, or to  
11 allergens at the time of an allergic disease.

12  
13 Indeed, the dendritic cells, under certain culture conditions, can cause an anergic  
14 reaction, i.e. the functional inactivation of the T lymphocytes instead of their  
15 activation. The culture of the dendritic cells in the presence of immunosuppressants  
16 like cyclosporin or histamine leads to a modification of the membrane antigens which  
17 will induce a tolerance response and not a cytotoxic response. This observation  
18 could have important implications in the context of organ grafts on the one hand and  
19 in the context of the treatments of the auto-immune diseases, on the other, like  
20 rheumatoid polyarthritis, myasthenia, insulino-dependent diabetes, multiple sclerosis,  
21 eczema, psoriasis, etc. and the allergic diseases. Example 8 illustrates this approach  
22 by showing the influence of cyclosporin A in the presence of RU 41740 on the  
23 maturation of the dendritic cells.

24  
25 Whatever the type of pathology concerned, the cell therapy can be carried out by  
26 administering to the human or animal patient autologous, homologous or xenologous  
27 cells after their modification *ex vivo*.

28  
29 The present invention thus relates to a process such as those described above in  
30 which the dendritic cells are treated *ex vivo* and administered after maturation to a  
31 human or animal patient in an autologous, homologous or xenologous manner for  
32 the prophylaxis, attenuation or treatment of cancerous, infectious, allergic or auto-  
33 immune diseases.

34

1 The use of RU 41740 or an analogue of the latter for the preparation of a  
2 composition comprising mature dendritic cells and/or activated macrophages and/or  
3 Langerhans cells of the skin, are also included in the scope of the present invention.

4

5 The inventors have shown that RU 41740 makes it possible to induce *in vitro* the  
6 maturation of Langerhans cells (Example 4). This property could thus be  
7 advantageously used to promote an immune response at the level of the skin or  
8 mucus membranes by topical administration of a composition containing RU 41740.  
9 Examples of indications for such a composition are in particular the *\_ingivitis* and the  
10 *parodontites*. The use of RU 41740 or an analogue of the latter for the preparation of  
11 a pharmaceutical composition for a topical or systemic administration hence also  
12 form part of this invention.

13

14 In another aspect of the invention, RU 41740 or an analogue of the latter is coupled  
15 to one or more antigens of interest, then administered directly *in vivo* in order to  
16 induce the production by the organism of mature dendritic cells or activated  
17 macrophages presenting the said antigens. In this realization of the invention, RU  
18 41740 or its analogue serves in fact as vector for the antigens of interest, and makes  
19 possible the presentation of these antigens to the immune system such that it  
20 induces the production of mature dendritic cells or activated macrophages  
21 presenting the said antigens.

22

23 Hence the invention relates to a process such as those described above in which the  
24 mature dendritic cells or the activated macrophages are produced directly *in vivo*.

25

26 The use of a coupling product formed between RU 41740 or an analogue of the  
27 latter and one or more antigens for the preparation of a composition able to induce  
28 the production of mature dendritic cells or activated macrophages presenting the  
29 said antigens are also included in the scope of this invention.

30

31 The mature dendritic cells obtained by processes such as those described above  
32 can be used in the treatment of various types of pathologies, in particular in anti-  
33 tumor immunotherapy, in the effort to combat infection or in order to increase the  
34 tolerance of the organism towards certain specific antigens. In a preferred

1 embodiment of the invention, the dendritic cells obtained by a process such as  
2 described above are used in the production of a composition able to promote an anti-  
3 tumor immune response.

4

5 Similarly, the use of dendritic cells obtained by a process of the present invention in  
6 the production of a composition able to promote an immune response against an  
7 infection by a micro-organism is an integral part of the invention.

8

9 In another preferred realization of the invention, the dendritic cells obtained by a  
10 process such as described above are incubated in the presence of an  
11 immunosuppressant and used in the production of a composition able to modify the  
12 immune response in the sense of a tolerance.

13

14 The mature dendritic cells produced by the processes of the invention can also be  
15 used to identify minor histocompatibility antigens. This technique consists of  
16 recovering the monocytes by making them differentiate into mature dendritic cells,  
17 then by using them as stimulant cells in a mixed lymphocyte culture reaction  
18 between individuals of the same compatible HLA family. This system makes it  
19 possible to detect disparities concerning the minor histocompatibility antigens and to  
20 be able to investigate in depth the compatibility or the incompatibilities between  
21 persons of the same family, and this presents definite advantages in the field of  
22 intra-familial or even extra-familial tissue and organ grafts. The use of dendritic cells  
23 obtained by a process of the invention for the detection and/or the characterization of  
24 the histocompatibility antigens also forms part of the present invention.

25

26 The Examples and Figures presented below as non-limiting will make it possible to  
27 demonstrate certain advantages and characteristics of the present invention.

28

29 **Legends to the Figures**

30 Figure 1 shows the change of the cell markers during the differentiation of the  
31 monocytes into dendritic cells on D0 (dotted curves = monocytic markers before  
32 treatment), D6 (curves in fine lines = immature dendritic cells) and D8 (curves in thick

1 lines = mature dendritic cells) after addition of RU 41740 at 25 µg/ml from D6  
2 onwards.

3  
4 Figure 2 illustrates the generation of cytotoxic T lines specific for the thyrocalcitonin  
5 peptide. The effector/target ratio used is indicated along the abscisse, whereas the  
6 percentage lysis of the target cells is indicated along the ordinate.  
7

8 Figure 3 demonstrates the presentation of the tetanus toxin by the dendritic cells  
9 derived from human monocytes cultivated in the presence of GM-CSF, IL-4 and RU  
10 41740. The incorporation of tritiated thymidine measured in counts per minute (cpm)  
11 is indicated along the ordinate.  
12

13 Figure 4 illustrates the influence of cyclosporin A (CsA) on the maturation of the  
14 dendritic cells derived from monocytes cultivated in the presence of GM-CSF, IL-4  
15 and RU 41740. The curves obtained in flow cytometry show the expression of CD83  
16 in the absence of CsA (4A) and in the presence of CsA at 5 µg/ml (4B). The Figures  
17 4C and 4D show the same curves for another marker of the dendritic cells, the DC  
18 Lamp antigen. The dotted curves were obtained with an anti-KLH primary antibody,  
19 not relevant for the dendritic cells.  
20

21 Figure 5 shows the orientation of the immune response towards a type Th2 immune  
22 response by the dendritic cells derived from monocytes and treated with cyclosporin  
23 A (CsA). The ordinate represents respectively the secretion of IL-12 (Figure 5A) and  
24 the ratio of the secretion of cytokines IFN- $\gamma$ /IL-10 (Th1/Th2) (Figure 5B) by dendritic  
25 cells derived from monocytes cultivated in the presence of GM-CSF, IL-4 and RU  
26 41740, and treated with cyclosporin A at 5 µg/ml (black columns) or untreated with  
27 cyclosporin A (white columns). Three experiments are shown for each condition. The  
28 results are presented in percentages with respect to the monocytic cells not treated  
29 with cyclosporin, the measurements of which were adjusted to 100.  
30

31 Figure 6 shows the results of mixed allogenic lymphocytic reactions carried out with  
32 dendritic cells obtained from purified monocytes of three different donors. Two types  
33 of dendritic cells were compared, the maturation of which was induced either by

1 TNF- $\alpha$  (200 U/ml) or by LCOS 1013 (25  $\mu$ g/ml) (curve marked "LCOS") for 48 hours.  
2 The horizontal axis corresponds to the number of irradiated dendritic cells deposited  
3 in each well, for a constant quantity of  $10^5$  T lymphocytes per well. The proliferation  
4 of the T lymphocytes, stimulated by the dendritic cells, is determined after 4 days of  
5 culture by the incorporation of tritiated thymidine (vertical axis).

6  
7

8 Figure 7 shows the results of mixed autologous lymphocytic reactions, carried out  
9 with dendritic cells obtained from the purified monocytes of three different donors.  
10 Two types of dendritic cells were compared, the maturation of which was induced  
11 either by TNF- $\alpha$  (200 U/ml) or by LCOS 1013 (25  $\mu$ g/ml) (curve marked "LCOS") for  
12 48 hours. The horizontal axis corresponds to the number of irradiated dendritic cells  
13 deposited in each well, for a constant quantity of  $10^5$  T lymphocytes per well. The  
14 proliferation of the T lymphocytes, stimulated by the dendritic cells, is determined  
15 after 5 days of culture by the incorporation of tritiated thymidine (vertical axis).

16

17 Figure 8 shows the results of mixed allogenic and autologous lymphocytic reactions  
18 carried out with dendritic cells, the maturation of which was induced either by TNF- $\alpha$   
19 (200 U/ml) or by LCOS 1013 at 5, 10 or 25  $\mu$ g/ml (curve marked "LCO") for 48 hours.  
20 The graphs were obtained in the same manner as the graphs shown in Figures 6  
21 and 7, respectively.

22

23 All of the techniques of cell culture, cell labelling, phenotyping by fluorometry, etc., as  
24 well as the reagents (antibodies, tetanus toxin, ...) used in the experiments  
25 described in the following examples have been described in detail in an article by  
26 Karine Duperrier et al., Journal of Immunological Methods 238 (2000), p. 119-131.

27

28

29

30 **Example 1: Process for the production of dendritic cells from human**  
31 **monocytes with RU 41740**

32 Peripheral blood is taken from the subject concerned. This blood is then centrifuged  
33 for 20 minutes at 200 g so as to diminish the contamination of the peripheral blood

1 cells by platelets. The upper part containing most of the platelets and the plasma is  
2 carefully removed before the mononucleated cells are purified by centrifuging them  
3 on a Ficoll separation gradient, the density of which is 1.077. The layer of  
4 mononucleated cells is recovered, then washed twice with PBS buffer and deposited  
5 on a gradient containing 4 discontinuous densities of Percoll in order to isolate the  
6 monocytes. This gradient is constituted by concentrations of Percoll in isotonic  
7 solution of 75% (6.5 ml), 50.5% (15 ml), 40% (3.5 ml) and 30% (3 ml) in a Dulbecco  
8 medium without magnesium nor calcium and containing 5% human serum. 75 to 100  
9 millions of cells are thus deposited in each tube and centrifuged at 1000 g during 25  
10 minutes at 4°C. The low density cells, principally the monocytes, are harvested at the  
11 interface between the concentrations 40% and 50.5%, and washed twice with PBS.  
12 They are then resuspended in a culture medium, then deposited on culture plates  
13 containing 6 wells at a density of  $5 \times 10^6$  cells per well in a final volume of 3 ml and  
14 left to adhere for 1 hour at 37°C. This adhesion step can be replaced by an  
15 additional purification of the monocytes by means of a negative purification system  
16 using a mixture of monoclonal antibodies combining an anti-CD3, CD7, CD19,  
17 CD45A, CD56 and anti-IgG with the aid of a Macs type microbead system (Miltenyi  
18 Biotec). This additional purification makes it possible to obtain concentrations of  
19 monocytes having a purity higher than 90%.

20 The cells are then placed in culture in culture wells at 37°C under 5% CO<sub>2</sub>. The  
21 medium which consists of RPMI contains 200 IU/ml of recombinant human GM-CSF  
22 and 500 IU/ml of recombinant human IL-4 in a final volume of 6 ml. On day 3 and  
23 day 5, the cultures are renewed by removing 3 ml and adding 3 ml of fresh medium  
24 with the cytokines. On day 6 the cells are transferred to Teflon pots and cultivated to  
25 a density of  $5 \times 10^5$  cells per pot in 3 ml in the presence of RU 41740 at different  
26 concentrations or recombinant human TNF- $\alpha$  at a concentration of 200 IU/ml for 2  
27 days. The cells are harvested on day 8, washed and cultivated in the absence of  
28 stimulation for a further 3 days.

29  
30 At the end of the culture period, the quality of the maturation is assessed by  
31 measuring the expression of the molecules CD80, 83, 86, 14, 1a, HLA-DR at the  
32 surface of the cells. The labellings revealed that more than 80% of the viable  
33 monocytes have matured to dendritic cells characterized by the following phenotype:

1 CD83+, CD86++, CD80++, HLA-DR+++, CD1a-, CD14-, CD40+++, CD54++, which  
2 places them in the group of highly differentiated tissue dendritic cells.

3 Figure No. 1 shows in fact that the molecules HLA-DR, HLA-DQ, CD40, CD54, CD80  
4 and CD86 are present on the majority of the cells on D8, after addition of RU 41740  
5 at 25 µg/ml, whereas the molecule CD14 is essentially no longer expressed.

6 In order to study the action of RU 41740 on the maturation of the dendritic cells (DC),  
7 different concentrations of the molecule were tested and compared with the action of  
8 TNF.

9 The following 3 experiments (a, b, c) were carried out starting from monocytes of the  
10 same donor.

11 a) The concentrations of RU 41740 tested here are 0.1 µg/ml, 1 µg/ml and 10 µg/ml.

12 Table 2 presents the results obtained with respect to the percentage of labelled cells  
13 and the mean fluorescence intensity (MFI).

14

	D0		D6		D8							
	Monocytes		Undifferentiated dendritic cells		RU 41740 0.1 µg/ml		RU 41740 1 µg/ml		RU 41740 10 µg/ml		TNF-alpha 200 IU/ml	
	%	MFI	%	MFI	%	MFI	%	MFI	%	MFI	%	MFI
HLA-DR	98.9	275	98.3	552	98.7	978	99.1	1164	98.9	1195	98.9	1225
CD 40	97.8	128	97.5	464	98.3	1340	98	1205	98.2	1328	98.4	1603
CD 54	98.6	41	95.6	85	96.4	220	96	210	95.6	282	97.4	295
CD 86	96.5	52	69.9	77	98.8	310	98.5	290	98	303	98.8	326
CD 83	0.2	325	5.5	119	82.1	156	76.1	165	84.7	184	84.5	173
HLA-DQ	24.2	48	63.2	61	86.4	160	88.8	153	84.1	174	84.3	157
CD 80	0.1	46	3.1	112	60.5	173	50.1	187	70	250	62.1	129
CD 14	96.2	5395	1.9	199	1.55	nd	0.97	nd	1.06	nd	0.87	nd

15

16 **Table 2:** Percentage (%) of labelled cells and mean fluorescence intensity (MFI) of  
17 the marker considered.

18

19 These results are expressed with a margin of error of ± 2.5%

1  
2 After 8 days of culture, the expression of the CD14 molecule has disappeared  
3 (percentage less than 1.5%), whatever the conditions of culture.

4  
5 The mean fluorescence intensity (MFI) of the labellings of the molecules HLA-DR,  
6 CD40, CD54 and CD86 appears weaker in the presence of the doses of RU 41740  
7 used than in the presence of TNF- $\alpha$ .

8  
9 On the other hand, the molecules CD83 and HLA-DQ are expressed slightly more in  
10 the presence of a concentration of RU 41740 of 10  $\mu\text{g}/\text{ml}$  than with TNF- $\alpha$ .

11  
12 Furthermore, the MFI of the CD80 molecule always appears higher in the presence  
13 of RU 41740.

14  
15 According to these results, it can be seen that RU 41740 induces the maturation of  
16 the dendritic cells, even at low concentrations. The MFI of the different markers  
17 however appears to be increased for the highest concentrations of RU 41740 tested,  
18 and approaches the results obtained in the presence of TNF- $\alpha$ .

19  
20 The action of RU 41740 on the dendritic cells at even higher concentrations was  
21 hence investigated in a second series of experiments.

22  
23 b) The concentrations of RU 41740 tested in this case are 5  $\mu\text{g}/\text{ml}$ , 10  $\mu\text{g}/\text{ml}$  and 50  
24  $\mu\text{g}/\text{ml}$ .

25  
26 The results are presented in Table No. 3.

27  
28 The MFI of the different molecules of adhesion, co-stimulation and class II HLA  
29 molecules appears to be increased in a manner dependent on the concentration of  
30 RU 41740 added to the culture medium. The CD40 molecule always exhibits a lower  
31 MFI in the presence of RU 41740 compared to the concentration obtained in the  
32 presence of TNF-alpha.

33

1 CD83, which is the specific marker of maturation, has a percentage and an intensity  
2 of fluorescence which also increase as a function of the quantity of RU 41740.

3

4 The molecule HLA-DQ exhibits a maximal expression at 10 µg/ml of RU 41740.

5

Monocytes	D0		D6		D8							
	%	MFI	%	MFI	RU 41740 5 µg/ml	RU 41740 10 µg/ml	RU 41740 50 µg/ml	TNF-alpha 200 IU/ml	%	MFI		
HLA-DR	99.2	275	98.3	552	98.9	1207	99.1	nd	99.3	nd	99.1	946
CD 40	97.8	128	97.5	464	99.8	1417	99.4	1441	99.8	1507	99.6	1728
CD 54	98.6	41	95.6	85	97.1	195	97	216	98.2	255	95.6	255
CD 86	96.5	52	69.9	77	98.9	267	98.7	271	99.7	248	99.5	273
CD 83	0.2	325	5.5	119	67.9	132	74.6	147	84.8	159	89.5	196
HLA-DQ	24.2	48	63.2	61	68.5	189	85.9	191	80.3	143	84.2	183
CD 80	0.1	46	3.1	112	63	86.7	64.6	101	76.1	95.8	70.5	93.5
CD 14	96.2	5395	1.9	199	0.47	nc	1.1	n	0.66	nd	0.61	nd
CD 1a					2.52	nd	1.55	nd	2.9	nd	0.21	nd

6

7 **Table No.3:** Percentage (%) of labelled cells and mean fluorescence intensity  
8 (MFI) of this marker (nd = could not be determined)

9

10 These results comprise a margin of error of  $\pm 2.5\%$ .

11

12 With a higher concentration (50 µg/ml) of RU 41740 compared to the experiment in  
13 Table 2, the MFI of the molecules CD40 and CD54 has increased, whereas the MFI  
14 of other molecules has diminished (molecules CD86 and HLA-DQ). Some markers,  
15 like CD80 and CD54, are expressed with the same intensity after a maturation with  
16 50 µg/ml of RU 41740 or with TNF- $\alpha$ .

17

1 Concentrations of RU 41740 both higher and lower than 50 µg/ml were then tested in  
2 a third series of experiments.

3

4 c) The concentrations of RU 41740 tested are 25 µg/ml, 50 µg/ml and 100 µg/ml.

5

6 The results are presented in Table No. 4.

7

	D0		D6		D8							
	Monocytes		Undifferentiated dendritic cells		RU 41740 25 µg/ml		RU 41740 50 µg/ml		RU 41740 100 µg/ml		TNF-alpha 200 IU/ml	
	%	MFI	%	MFI	%	MFI	%	MFI	%	MFI	%	MFI
HLA-DR	99.2	275	98.3	552	98.5	630	97.5	823	99.4	682	99.4	694
CD 40	97.8	128	97.5	464	99.7	1592	99.1	1958	99.8	2088	99.3	1480
CD 54	98.6	41	95.6	85	98.5	280	97.2	321	98.9	361	98.2	249
CD 86	96.5	52	69.9	77	99.3	284	98.3	291	99.6	295	99.5	284
CD 83	0.2	325	5.5	119	86.6	192	91.2	227	92.8	213	89	166
HLA-DQ	24.2	48	63.2	61	79	109	84.8	123	78.8	118	nd	nd
CD 80	0.1	46	3.1	112	74	128	82.4	165	90.8	196	nd	nd
CD 14	96.2	5395	1.9	199	1.03	nd	4.07	nd	1.75	nd	3.27	nd

8

9 **Table No. 4:** Percentage (%) of labelled cells and mean fluorescence intensity  
10 (MFI) of this marker (nd = could not be determined).

11

12 These results comprise a margin of error of  $\pm 2.5\%$ .

13

14 The molecules CD40, CD54, CD86 and HLA-DR are present on more than 97% of  
15 the cells at the three concentrations of RU 41740. Their MFI are comparable to those  
16 obtained with TNF- $\alpha$  for a concentration of 25 µg/ml of RU 41740. However, in this  
17 experiment they continue to increase with higher concentrations of RU 41740.

18

1 CD83 is present on a very high percentage of cells at 100 µg/ml and at 50 µg/ml,  
2 higher than the results obtained with TNF- $\alpha$ . Its MFI appears to be higher with 50  
3 µg/ml.

4

5 At 100 µg/ml of RU 41740, the fluorescence intensities of the class II HLA molecules  
6 tend to diminish, and this may suggest that this concentration is the limit  
7 concentration of RU 41740.

8

9 All of the experiments suggest that the optimal dose of RU 41740 is situated  
10 between 10 and 50 pg/ml.

11

12 **Example 2: Process for the production of dendritic cells from human  
13 hematopoietic CD34+ stem cells with RU 41740**

14

15 \* Experimental conditions:

16 Purification: After Ficoll, the CD34+ represented 4.2% of the mononucleated cells  
17 (MNC).

18 After purification by positive selection with the MAC System procedure (Miltenyi  
19 Biotec) with beads coated with an anti-CD34 antibody, 90% of the cells are CD34+.

20

21 Placing in culture:

22 - *Culture medium*: RPMI containing 10% of FCS, 2% of penicillin/streptomycin,  
23 1% of glutamine and 1% of sodium bicarbonate.

24

25 Culture in 2 ml wells with  $5 \times 10^5$  cells per well.

26

27 - *cytokines present in the culture medium*:

28

29 from D0 to D5: FCS at 25 ng/ml, GM-CSF at 100 ng/ml and  
30 either TNF- $\alpha$  at 2.5 ng/ml  
31 or RU 41740 at 6.25 ng/ml  
32 from D5 to D14: GM-CSF at 100 ng/ml

33

**1** Duplication of the cultures: - the cells are homogenized in the well, then 1 ml sample  
**2** is taken and deposited in a fresh well. 1 ml of culture medium is then added to the  
**3** fresh well and the old one, as well as GM-CSF as a function of the medium added.

4

5 Markers: CD34 – CD45 – CD14 – HLA-DR – CD40 – CD54 – CD83 – CD86 – CD1a.

6

7 A fluorescence-labelled anti-KLH primary antibody was used as control in order to be  
8 able to subtract the non-specific fluorescence of the signals obtained.

9

## 10 \* Results:

11

12

	D8		D12		D14	
	TNF- $\alpha$	RU 41740	TNF- $\alpha$	RU 41740	TNF- $\alpha$	RU 41740
CD14	40	37	63.2	47.4	54.1	52.5
CD34	0.7	17				
CD45	96	96				
CD83	0.5	0.2	1.3	1.3	0.8	1
CD86	13	11	7.4	10.8	2.2	4.7
CD1a	8.7	17	8.4	17.5	10.3	28.9
CD40	44	38	64.3	59.4		
CD54	33	56	61.8	57.9		
HLA-DR	88	80	80.3	65.3	69.9	69.54
HLA-DQ			54.1	52.3		
CD80			5.3	16		

13

14

**Table No 5:** Percentage of cells expressing a cell marker at different times of culture

16

17 CD1a is expressed more with RU 41740 (17.5% of cells on D12) than with TNF- $\alpha$ ,  
18 unlike CD14, which is expressed more with TNF- $\alpha$  at the cell surface.

18

20 The levels of expression in the presence of RU 41740 of CD40, CD54 or HLA-DR  
21 are essentially identical to the levels of expression in the presence of TNF- $\alpha$ .

22

23 CD83 is not expressed whatever the conditions

24

1   **Example 3:           Pr c ss for the production of dendritic c lls starting from**  
2   **CD34+ cells of human cord blood with RU 41740**

3  
4   \* The experimental conditions are similar to Example 2, except the fact that the cells  
5   are derived from cord blood:

6  
7  
8   Purification: After Ficoll, the CD34+ cells represent 0.83% of the mononucleated  
9   cells (MNC).

10   After purification by positive selection, 18.1% of CD34+ are obtained.

11    $2 \times 10^6$  cells were obtained.

12  
13   Duplication: on D6, D7,D8, D10 and D12.

14  
15   \* Results: The results are presented in Table No 6.

	D7		D9		D10		D12		D13		D14	
	TNF- $\alpha$ (200 IU/ml)	RU 41740 (10 $\mu$ g/ml)	TNF- $\alpha$ RU 41740	RU 41740								
CD14	32	20.39	59.6	43.52	60	50.05	66.77	59.23	57.73	52.28	46.77	30.88
CD34	19.79	19.92	2.53	2.94	2.26	2.08	0.69	1.25	0.45	0.61	0.38	0.57
CD45	99.84	97.57	99.96	99.76	99.97	99.86	99.85	99.92	99.69	99.82	99.93	99.91
CD16	2.24	3.68	2.16	2.78	2.11	4.89						
CD83	1.09	0.39	4.24	4.9	2.46	1.19	0.71	1.35	3.19	3.41	1.22	0.83
CD86	11.61	11.97	22.23	13.69	9.23	7.48	13.94	11.91	12.78	17.1	19.33	10.56
CD1a	4.41	13.95	23.75	20.32	20.63	22.68	27.9	20.14	36.13	23.67	34.2	16.63
CD40							75.91	55.23	63.35	56.02	64.56	41.47
CD54							74.66	65.62	61.7	58.57	64.4	41.69
HLA-DR							81.34	73.8	73.04	63.28	57.84	37.69

16  
17   **Table No.6**  
18   PERCENTAGE OF LABELLED CELLS  
19   CD34+ cells of cord blood placed in culture until D6 with GM-CSF, SCF and RU  
20   41740 (10  $\mu$ g/ml) or TNF- $\alpha$  (200 IU/ml), then from D6 to D14 with GM-CSF.

1  
2  
3  
4 In the two culture protocols, the changes in the expression of the surface molecules  
5 show the same tendencies:  
6 - increase of CD14 up to D12, then diminution  
7 - diminution then disappearance of the molecule CD34 on D12  
8 - very weak expression of CD83 and CD16 which remains stable.  
9

10 CD1a is expressed early at D7 on the cells treated with RU 41740 then stabilizes  
11 around 23% at D14, thus revealing more rapid kinetics with RU 41740 than with  
12 TNF- $\alpha$ .

13  
14 After D12, the molecules CD40, CD54 and HLA-DR are expressed to a lesser extent  
15 in the presence of RU 41740 than in the presence of TNF- $\alpha$ .  
16

17 **Example 4: Process of differentiation of Langerhans cells**  
18

19 The stem cells are obtained after a passage of cord blood through a Ficoll gradient.  
20 The mononucleated CD34+ cells are purified by positive selection with an anti-CD34  
21 monoclonal antibody (Immuno 133.3, Immunotech Marseille, France). After purification,  
22 more than 90% of the cells are CD34+.

23  
24 These CD34+ cells are then cultivated in the presence of GM-CSF (100 ng/ml) and  
25 TNF- $\alpha$  (2.5 ng/ml) or RU 41740 (10  $\mu$ g/ml) for 12 days in a medium: RPMI – FCS  
26 10% - penicillin streptomycin 2%, glutamine 1% - sodium bicarbonate 1% and 10 mM  
27 of HEPES. At the end of the culture period at D12, the cells are labelled with the anti-  
28 CD1a, CD14, Lag, E-cadherin, DR and DQ antibodies so as to identify the  
29 Langerhans cells which are Lag+, CD1a+, CD14-, DR+ and DQ+.

30  
31 The results presented in Table No. 7 show a better efficacy of RU 41740 than  
32 TNF- $\alpha$  in the differentiation of the Langerhans cells.  
33  
34

	TNF- $\alpha$	RU 41740
CD1a+ DR+	8%	17%
Lag+ DR+	5.2%	8.6%

1  
2 **Table No 7**  
3

4 **Example 5: Process for the production of mature dendritic cells from the**  
5 **mononucleated cells of the dog with RU 41740.**  
6

7 An elutriator is an apparatus which makes it possible to subject cells to two opposing  
8 forces, one centrifugal and the other centripetal, in a liquid medium. This makes it  
9 possible to separate the cells according to their size and their density, while  
10 maintaining them in their physiological medium. This procedure is particularly  
11 advantageous for separating the dog cells (monocytes/lymphocytes) which form  
12 aggregates in gradients of the Ficoll type.  
13

14 **ELUTRIATION MEDIUM:**  
15 PBS 1X – FCS 2% - EDTA 0.01%  
16

17 **PREPARATION OF THE MONONUCLEATED CELLS:**  
18

19 The pouch of blood is collected on CPD (citrate phosphate dextrose), the blood is  
20 diluted with sodium chloride, centrifuged at 800 rev./min for 15 min without braking in  
21 order to remove as many platelets as possible.  
22

23 A Ficoll is carried out at 1600 rev./min for 25 min without braking.  
24

25 The MNC are recovered and washed twice with PBS (the first to remove platelets).  
26 The cell concentration is  $5 \times 10^6$  cells/ml in PBS or in the elutriation medium.  
27

28 **PROTOCOL FOR OBTAINING MONOCYTES**  
29

30 *Flow rate:* 25 ml/min (control with the pump according to the calibration line)  
31

1 Vary the speed of centrifugation:  
2 Loading of the cells at 3200 rev./min in 300 ml  
3 3000 rev/min in 250 ml  
4 2700 rev/min in 200 ml  
5 2500 rev/min in 200 ml  
6 2300 rev/min in 200 ml  
7 2100 rev/min in 200 ml  
8  
9 Rotor off in 200 ml

10  
11 **RESULTS**  
12

13 The fraction obtained at 2700 rev/min contains monocytes with a purity higher than  
14 80%.

15  
16 **CULTURE**  
17

18 The dog monocytes are cultivated in the same manner as human monocytes and  
19 with the same human differentiation factors: GM-CSF, TNF or RU 41740. On the  
20 other hand, IL4 is specific for the canine species. The dendritic cells thus obtained  
21 possess the same morphology as dendrites, but the surface markers are not  
22 comparable to those of man although they are CD14-, DR+ and DQ+, because we  
23 do not have available specific antibodies in this species. RU 41740 has the same  
24 effects as TNF- $\alpha$ .

25  
26 **Example 6:      Use of mature dendritic cells in the emergence of an anti-**  
27 **tumor response.**  
28

29 Thyrocalcitonin is a relatively weak immunogenic tumor antigen expressed strongly  
30 in medullary cancers of the thyroid. In the system used, the inventors have been able  
31 to reproduce T lymphocytic clones directed against thyrocalcitonin. They are  
32 cytotoxic clones capable of having an anti-tumor activity in the cancers caused by  
33 thyrocalcitonin.

1  
2 Figure 2 illustrates the generation of cytotoxic T lines specific for the thyrocalcitonin  
3 peptide.

4  
5 Dendritic cells derived from monocytes after culture in the presence of GM-CSF, IL-4  
6 and RU 41740 are incubated with the thyrocalcitonin peptide, then placed in culture  
7 in the presence of autologous T lymphocytes in order to induce the activation of T  
8 lymphocytes specific for the peptide.

9  
10 After several stimulations of the T lymphocytes with the aid of dendritic cells then  
11 with EBV cells incubated with the peptide, lines of cytotoxic T cells (H10 and B7)  
12 capable of lysing specifically target EBV cells incubated with the thyrocalcitonin  
13 peptide could be generated.

14  
15 **Example 7: Use of mature DC in anti-infectious activities**

16  
17 By using the tetanus anatoxin as antigen presented by the MODC (Monocyte  
18 Dendritic Cells), it was possible to generate anti-tetanus anatoxin cytotoxic lines,  
19 which quite obviously demonstrates that this system makes it possible to have a  
20 primary immunization towards antigens of the infectious type.

21  
22 Figure 3 represents a secondary response of the anti-tetanus anatoxin lines by the  
23 dendritic cells derived from human monocytes cultivated in the presence of GM-CSF,  
24 IL-4 and RU 41740

25  
26 **Example 8: Use of mature dendritic cells in the induction of a tolerance  
27 response.**

28  
29 The dendritic cells can cause an anergic reaction under certain culture conditions.  
30 The culture of these cells in the presence of immunosuppressants like cyclosporin or  
31 histamine leads to a modification of the membrane antigens which will induce a  
32 tolerance response and not a cytotoxic response. In this manner, it is hence possible  
33 to educate the dendritic cells in order to direct them towards a tolerance reaction.

1  
2 We give as an example the influence of cyclosporin A (CsA) on the maturation of the  
3 dendritic cells.

4  
5 Purified monocytes were cultivated in the presence of GM-CSF and IL-4 for 6 days  
6 and in the presence of RU 41740 for 2 days more, in a medium containing 10% AB  
7 type human serum. 1 µg/ml or 5 µg/ml of CsA were or were not added right at the  
8 start of culture. The expression of the molecules HLA-DR, CD83, CD86, CD80,  
9 CD40 and CD1a was analyzed by flow cytometry (Table No 8).

10  
11

	Without CsA		CsA (1µg/ml)		CsA (5µg/ml)	
	% ± SD	MFI	% ± SD	MFI	% ± SD	MFI
HLA-DR	99 ± 0.8	1605	98.8 ± 0.9	1504	99.2 ± 0.7	1101
CD40	98.9 ± 0.6	1697	98.4 ± 0.8	1314	99 ± 0.6	1278
CD86	97.7 ± 1.8	373	98.6 ± 1.2	318	96.4 ± 3.3	253
CD83	77.1 ± 8.5	169	64.2 ± 20	170	49.9 ± 6.2	132
CD80	78.1 ± 5.6	216	68.9 ± 2.6	162	58.3 ± 17	143
CD1a	14.3 ± 9.5	45.5	27 ± 7	74	25.9 ± 6.5	78

12  
13 **Table No 8**  
14  
15 This study demonstrates that cyclosporin causes a marked diminution of the  
16 expression of the molecules CD83 and CD80 as well as an increase of the  
17 expression of CD1a. A graphic analysis (Figure 4) reveals in reality the existence of  
18 two cell populations, one CD83+ and the other CD83- which has immunoregulatory  
19 properties.

20 Indeed the dendritic cells in the presence of CsA (CsA-MODC) are capable of  
21 directing the response of the T lymphocytes towards a type TH2 response which  
22 promotes a common suppressive reaction.

23  
24 Figure 5 illustrates this polarization of the immune response towards a type Th2  
25 response by dendritic cells derived from monocytes and treated with cyclosporin A.  
26

1 Dendritic cells derived from monocytes cultivated in the presence of GM-CSF, IL-4  
2 and RU 41740 and treated with cyclosporin A secrete less IL-12 than the untreated  
3 dendritic cells (Figure 5A).

4

5 Furthermore, the ratio of the secretion of cytokines IFN- $\gamma$ /IL-10 (Th1/Th2) by T cells is  
6 diminished when the T cells are stimulated by dendritic cells treated with cyclosporin  
7 (Figure 5B).

8

9 **Example 9: Use of mature DC to induce a mixed allogenic or autologous  
10 lymphocytic culture.**

11

12 In the presence of mature MODC, the allogenic T lymphocytes, on day 6 and even  
13 on day 8 have an extremely extensive capacity to proliferate, very much higher than  
14 that which is observed with the use of the allogenic T lymphocytes and allogenic  
15 monocytes. It is the same for a mixed autologous culture.

16

17 Mixed autologous lymphocytic cultures were hence induced by cells derived from  
18 monocytes (MODCs) generated in the presence of GM-CSF (200 IU/ml, IL-4 (500  
19 IU/ml and RU 41740 (10  $\mu$ g/ml).

20

21 Ten thousand MODCs, irradiated at 30 Grays, are cultivated with different  
22 lymphocytic subpopulations selected either by means of Dynal magnetic beads  
23 (CD4+ and CD8+) or with the select module of the FACS Calibur (CD8bright, CD28-  
24 and CD8bright, CD28+ autos). In Table 8, the values indicated represent the  
25 incorporation of tritiated thymidine after mixed autologous culture, except(\*\*). The  
26 experiments are carried out in triplicate, except (\*), in duplicate.

27

28

29

30

31

32

Condition	Values			Student test compared with negative control P=
(100.000 CD4+ autos)+ (35.000 CD4+ autos)	7898	10720	8613	
(100.000 CD4+ allos) + (35.000 CD4+ allos) (**)	119066	193392	206319	3.827E-03
(100.000 CD4+ autos) + (35.000 CD28- autos)	37808	45223	42027	1.458E -04
(100.000 CD4+ autos) + (35.000 CD28+ autos)	32990	54800		2.394E -02
(100.000 CD4+ autos) + (100.000 CD8+ autos) (*)	13985	12941	13573	3.978E -03

1  
2  
3

Condition	Mean	Standard deviation
(100.000 CD4+ autos)+ (35.000 CD4+ autos)	9077	692
(100.000 CD4+ allos) + (35.000 CD4+ allos) (**)	172926	22198
(100.000 CD4+ autos) + (35.000 CD8bright 28- autos)	41686	1753
(100.000 CD4+ autos) + (35.000 CD8bright CD28+ autos) (*)	43895	7711
(100.000 CD4+ autos) + (100.000 CD8+ autos)	13500	248

4  
5

#### Table No. 9

6  
7

#### Example 10: Processes for the production of LCOS 1013 and LCOS 1014.


8

9

#### A. GENERAL PRESENTATION OF LCOS 1013

10 LCOS 1013 is an analogue of RU 41740 consisting of a set of substances extracted  
11 from a culture lysate of *Klebsiella pneumoniae*. Its mode of production is based on

1 the sequence of steps or stages, the general scheme of which is presented below.  
2 Media usable for the cultures as well as a summary presentation of how each step  
3 proceeds are described in more detail after this diagram.  
4 The production technique described below, purely as a guide, corresponds to an  
5 operational unit based on the volume of bacterial culture obtained in a 600 litres  
6 fermenter.



1  
2

3      **B. DESCRIPTION OF DIFFERENT MEDIA USABLE FOR THE CULTURE OF**  
4      **BACTERIA**

5      The culture of bacteria with a view to producing LCOS 1013 following the sequence  
6      of steps specified above can be carried out by using the culture media containing the  
7      following constituents:

8      Nutritive broth

9      Papaïn soya peptone	4 ± 2 g/l
10     Yeast autolysate	4 ± 2 g/l
11     Sodium chloride	5 ± 2 g/l
12     Sodium hydroxide	qsp for pH 7.4 ± 0.2

13     Roux dish

14     Sodium chloride	5 ± 2 g/l
15     Anhydrous glucose	5 ± 2 g/l
16     Yeast autolysate	12 ± 3 g/l
17     Papaïn soya peptone	5 ± 2 g/l
18     Gelose	30 ± 4 g/l
19     Sodium hydroxide	qsp for pH 7.5 ± 0.2
20     Dipotassium phosphate	4 ± 2 g/l
21     Monopotassium phosphate	0.5 ± 0.9 g/l

22     Preculture medium

23     Papaïn soya peptone	20 ± 3 g/l
24     Yeast autolysate	10 ± 2 g/l
25     Sodium chloride	5 ± 2 g/l
26     Dipotassium phosphate	3.5 ± 1 g/l
27     Monopotassium phosphate	1 to 2 g/l

28     Culture medium for fermenter

29     Autolysate of baker's yeast	10 ± 2 g/l
30     Sodium chloride	5 ± 2 g/l
31     Papaïn soya peptone	20 ± 3 g/l
32     Dipotassium phosphate	3.5 ± 1 g/l

1 Monopotassium phosphate 1 to 2 g/l

2

3 **C. DETAILED DESCRIPTION OF THE DIFFERENT STAGES OF**  
4 **PRODUCTION OF LCOS 1013**

5 **STAGE 1: Preparation of the inoculum**

6 The objective of this stage is to carry out, on gelosed medium in a Roux dish, the  
7 culture of *Klebsiella pneumoniae* necessary for the inoculation of a preculture in  
8 liquid medium, starting from a cryotube or a lyophilizate derived from the work bank.

9 The work bank is carried out for example starting from a strain of *Klebsiella*  
10 *pneumoniae* of the Pasteur Institute reference CIP 52.145

11 For that, the strain is revived by preparing a bacterial suspension in nutrient broth,  
12 starting from which Roux dishes are inoculated, which are then incubated at 37°C ±  
13 0.5 for 20 to 24 hours.

14

15 **STAGE 2: Precultures**

16

17 Starting from the inoculum prepared at stage 1, a preculture is prepared in a 3 litres  
18 bottle, which will be used to inoculate a 35 l fermenter, which in turn will be used in a  
19 second stage to inoculate a 600 l fermenter.

20 The first preculture is prepared in the preculture medium described above, to which  
21 is added a sterile solution of glucose containing 30 g of glucose for 3 litres. The  
22 second preculture, of 35 litres, is prepared in the culture medium for the fermenter  
23 described above, to which 400 g of glucose are added.

24 Satellite bottles containing respectively a sterile solution of 10 N sodium hydroxide, a  
25 sterile solution of orthophosphoric acid diluted to 1/2 and a sterile anti-foam solution,  
26 can be used for the second preculture, in the fermenter, in order in particular to  
27 maintain the pH around 6.5 throughout the entire preculture, lasting namely for about  
28 5 hours at about 37°C, with shaking.

29

30 **STAGE 3: Culture in fermenter**

31 The objective of this step is to produce under defined conditions in the fermenter a  
32 bacterial culture containing  $1.7 \times 10^{10}$  or more bacteria/ml in order to make possible  
33 the subsequent extraction of a satisfactory quantity of product.

1 For that, the suspension of bacteria contained in the 35 l fermenter is transferred to a  
2 600 litres fermenter containing the culture medium for the fermenter described  
3 above, to which 5 kg of glucose were added.  
4 As in the case of the 35 litres of preculture, satellite vats containing respectively a  
5 sterile solution of 10 N sodium hydroxide and a sterile solution of orthophosphoric  
6 acid diluted to 1/2 are used for the adjustment of the pH around 6.5 as well as a  
7 satellite vat containing a sterile anti-foam solution. The culture is grown during about  
8 7 hours at  $37^{\circ}\text{C} \pm 1^{\circ}\text{C}$ , with shaking.

9  
10 **STAGE 4: End of culture and addition of the lysing agents**  
11  
12 The objective of this stage is to inactivate the culture by the action of lysing agents  
13 and by heating from 55 to  $75^{\circ}\text{C}$  for a time equal to or exceeding 40 minutes. For that  
14 the following lysing agents are used:

15 Sterile solution of polysorbate 80,  
16 Sterile solution of EDTA,  
17 Sterile solution of lysozyme hydrochloride.

18 At the end of culture, the pH is brought to  $5.8 \pm 0.3$  with the aid of a sterile solution of  
19 orthophosphoric acid, then the above lysing agents are transferred to the culture.  
20 The temperature of the content of the fermenter is then brought to  $65^{\circ}\text{C} \pm 10^{\circ}\text{C}$  and  
21 maintained at this temperature with shaking for at least 40 minutes.  
22 The biolysate obtained is then transferred to an industrial lysis vat (preheated to  
23  $65^{\circ}\text{C} \pm 10^{\circ}\text{C}$ ) and maintained at this temperature for at least 20 minutes, before  
24 being brought to  $37^{\circ}\text{C} \pm 2^{\circ}\text{C}$ .

25  
26 **STAGE 5: Lysis**  
27  
28 The lysis step consists of rupturing the cell wall of the bacteria enzymatically, and  
29 this leads to the release of the cytoplasmic constituents of the microbial cells. It is  
30 carried out by maintaining the prelysed suspension of the preceding stage at  $37^{\circ}\text{C} \pm$   
31  $2^{\circ}\text{C}$  in the lysis vat for at least 6 days.

32

1   **STAGE 6 : Molecular sieving and concentration**

2  
3   In this step the volume of crude lysate is reduced by a half in order to diminish the  
4   amount to be treated in the following stages. The concentration is carried out for  
5   example on an ultrafilter equipped with a filtering cartridge of the CARBOSEP type  
6   with a  $\leq$  100 KD cut-off threshold, thus removing unbound small molecules.

7  
8   **STAGE 7: Lyophilization of the lysate**

9  
10   In order to obtain the crude lysate derived from stage 6 in solid form making possible  
11   subsequent extractions with solvents, a lyophilization operation is carried out  
12   immediately after the concentration stage. A brown powder, sticky to the touch, is  
13   thus obtained.

14  
15   **STAGE 8: Extraction with acetone:**

16  
17   The lyophilized lysate of LCOS 1013, derived from Stage 7, contains lipids that are  
18   partially removed by solid-liquid extraction, using acetone at room temperature.

19   The volume of acetone used is proportional to the mass of the lyophilisate. This  
20   volume is obtained according to the following calculation:

21    $10 \times \text{mass to be extracted} \leq V_{\text{solvent}} \leq 20 \times \text{mass to be extracted}$ , with preferably ( $V$   
22   solvent/mass to be extracted) = 15

23   The product is recovered by centrifugation, then dried.

24  
25   **STAGE 9: Extraction with methanol**

26  
27   After extraction with acetone, the product obtained in stage 8 still contains residual  
28   lipids and pigments which are removed by solid-liquid extraction using methanol at  
29   room temperature.

30   The volume of methanol used is proportional to the mass of the lyophilisate.  
31   This volume is obtained according to the following calculation:  
32    $10 \times \text{mass to be extracted} \leq V_{\text{solvent}} \leq 20 \times \text{mass to be extracted}$ , with preferably ( $V$   
33   solvent/mass to be extracted) = 15

1 The product is recovered by centrifugation, then dried.

2

3 **STAGE 10: Redissolution**

4

5 "The methanol extract" obtained at stage 9 is redissolved in aqueous solution in  
6 order to make possible the subsequent isolation of the product by centrifugation and  
7 ultrafiltration.

8

9 **STAGE 11: Centrifugation**

10

11 The crude extract in suspension derived from stage 10 contains denatured proteins  
12 and materials insoluble in water which are removed by centrifugation between 14000  
13 and 18000 g.

14 The centrifuged product has a slightly colloidal appearance and is beige brown in  
15 colour.

16

17 **STAGE 12: Ultrafiltration**

18

19 This stage represents the essential step in the isolation of the product.

20 The product derived from stage 11 contains substances of different molecular sizes:  
21 mineral salts, proteins, glycoproteins, etc...

22 The macromolecules of MW  $\geq$  300000 constituting the product are isolated by  
23 ultrafiltration through a membrane with a cut-off threshold of 300 KD.

24

25 The product, once introduced into the interior of the apparatus is circulated  
26 continually by means of a pump in a closed circuit comprising an ultrafilter. The  
27 medium is maintained homogeneous by means of shaking. The pressure created by  
28 the pump on the membrane filter compels a part of the solute to pass through this  
29 membrane (permeate).

30

31 The part retained (retentate) remains in circulation. Since the operation proceeds at  
32 constant volume, the loss of volume is compensated continuously by the supply of  
33 the same volume of water.

- 1 At the end of the operation the solution is ultrafiltered.  
2 The ultrafiltrate obtained is a slightly yellow translucent liquid solution.

3

4 **STAGE 13: Filtration**

5

6 The clarification of the centrifugation supernatant obtained in stage 11 is improved  
7 by filtration through a membrane with nominal retention of 1.2 µm.

8

9 In this way an opalescent “solution of glycoproteins”, light beige to cream in colour, is  
10 obtained.

11

12 **STAGE 14: Lyophilization**

13

14 In order to ensure that the product is well preserved, the solution derived from stage  
15 13 is then lyophilized by a procedure comprising a freezing step, then the  
16 lyophilization properly so called.

17 The lyophilized glycoproteins have the appearance of a flocculent, creamy white,  
18 hygroscopic powder.

19

20 **STAGE 15: Mixing**

21

22 The objective of this last step is to homogenize the lyophilized glycoproteins derived  
23 from stage 14.

24

25 Spraying may advantageously replace lyophilization and mixing (LCOS 1014)

26

27 **Example 11: Study of the effect of the molecule LCOS 1013 on the**  
28 **maturation of the dendritic cells derived from human**  
29 **monocytes.**

30

31 The effect of LCOS 1013 on the maturation of the dendritic cells generated from  
32 human monocytes was studied on cells derived from 3 different donors, by  
33 comparison with TNF-α.

1

2       A. Protocol

3 - The purified monocytes (more than 90%) were placed in culture in RPMI medium  
4 containing 10% AB human serum in the presence of growth factors GM-CSF (200  
5 U/ml) and IL-4 (500 U/ml) for 6 days in order to induce the differentiation of the  
6 monocytes into immature dendritic cells. The maturation of the cells was induced by  
7 addition of TNF- $\alpha$  (200 U/ml) or the compound LCOS 1013 (25  $\mu$ g/ml) for 48 hours.

8 - The phenotype of the cells thus generated (after 8 days of culture) was examined  
9 by flow cytometry. The expression of the marker specific for maturation of the  
10 dendritic cells (CD83), of the co-stimulatory molecules CD80, CD86, CD40, of the  
11 adhesion molecule CD54, of the class II HLA-DR molecule of the major  
12 histocompatibility complex was analyzed. The expression of the CD1a molecule,  
13 specific marker of the Langerhans cells, immature dendritic cells, was also tested.

14 - The functional properties of the cells were studied with the aid of mixed lymphocytic  
15 reactions (MLR). In order to do this, a range of concentrations of dendritic cells was  
16 placed in the presence of a defined concentration of allogenic T lymphocytes (mixed  
17 allogenic reaction) or autologous T lymphocytes (mixed autologous reaction) for 4  
18 and 5 days, respectively. The proliferation of the T lymphocytes was determined by  
19 incorporation of tritiated thymidine. The experimental protocols for the mixed  
20 lymphocytic reactions are described in more detail in the article of K. Duperrier et al.  
21 cited above.

22

23       B. Results

24

25 *Phenotype of the dendritic cells*

26

27 The Tables 10 to 12 below summarize the percentages of expression of the different  
28 markers as well as the mean fluorescence intensity (MFI) of each marker (in  
29 parentheses).

Donor 1	CD83	CD80	CD86	CD40	CD54	HLA-DR	CD1a
TNF- $\alpha$	91% (132)	69.7% (85)	99.5% (209)	99.4% (1084)	98.4% (195)	99.5% (803)	13.2% (28)
LCOS 1013	84.6% (157)	<b>93.2%</b> (134)	99.7% (214)	99.7% (1270)	99.2% (306)	99.7% (502)	10.8% (20)

1  
2 **Table No.10**  
3  
4  
5

Donor 2	CD83	CD80	CD86	CD40	CD54	HLA-DR	CD1a
TNF- $\alpha$	88% (221)	55.1% (89)	99.1% (299)	99.2% (1104)	97.8% (355)	98.6% (1108)	20.6% (215)
LCOS 1013	81.4% (242)	<b>81.8%</b> (169)	98.1% (298)	99.3% (1441)	97.5% (416)	98.8% (1102)	11.1% (299)

6  
7 **Table No.11**  
8  
9  
10

Donor 3	CD83	CD80	CD86	CD40	CD54	HLA-DR	CD1a
TNF- $\alpha$	91.8% (108)	48.7% (65)	98.5% (209)	98.7% (918)	95.9% (154)	98.9% (768)	Neg.
LCOS 1013	92.3% (118)	<b>89.4%</b> (104)	98.2% (214)	98.7% (1270)	98.4% (288)	97.5% (588)	Neg.

11  
12 **Table No.12**  
13  
14

15 The dendritic cells generated in the presence of the molecule LCOS 1013 exhibit a  
16 phenotype characteristic of the mature dendritic cells, as a result of the expression of  
17 the CD83 molecules, of the co-stimulatory and adhesion molecules as well as the  
18 weak expression of CD1a.

19  
20 It appears, however, that the percentage of expression, as well as the MFI of the  
21 molecule CD80 are increased in the presence of the molecule LCOS 1013,  
22 compared with TNF- $\alpha$ , as is the MFI of the molecules CD40 and CD54.

23  
24 These results suggest a differential effect of the molecule LCOS 1013 compared  
25 with TNF- $\alpha$  as regards the maturation of the dendritic cells.

1   *Functions of the dendritic cells*

2  
3   The results of the mixed allogenic lymphocytic reactions are illustrated in Figure 6.  
4   They show that the dendritic cells cultivated in the presence of LCOS 1013 exhibit a  
5   high allostimulatory capacity, comparable to that of the cells generated in the  
6   presence of TNF- $\alpha$ .

7  
8   The results of the mixed autologous lymphocytic reactions are presented in Figure 7.  
9   Remarkably, the dendritic cells cultivated in the presence of LCOS 1013 exhibit a  
10   capacity to stimulate autologous T lymphocytes much greater than the cells  
11   generated in the presence of TNF- $\alpha$  (at least 5 fold higher).

12  
13           **C. Conclusion**

14   The results above show that the molecule LCOS 1013 induces in an efficacious  
15   manner the maturation of the dendritic cells generated from human monocytes, at  
16   the phenotypic and functional levels.

17   It is interesting to note however that the expression of the molecule CD80 is greatly  
18   increased in the presence of LCOS 1013 and that the cells induce a strong  
19   autologous response by comparison with TNF- $\alpha$ , and do this in the case of the 3  
20   donors tested.

21  
22   This is in agreement with the results presented by Scheinecker et al. (Journal of  
23   Immunology, 1998, 161: 3966-3973), which suggest that the molecule CD80 might  
24   play an essential role in the initiation of the mixed autologous reaction.

25  
26   **Example 12 :      Study of the effect of different concentrations of LCOS 1013  
27                          on the maturation of the dendritic cells.**

28  
29   The effect of different concentrations of LCOS 1013 on the maturation of the  
30   dendritic cells generated from human monocytes from a single donor was studied in  
31   comparison with TNF- $\alpha$ .

32   The concentrations tested for LCOS 1013 are 5, 10 and 25  $\mu$ g/ml and 200 U/ml for  
33   TNF- $\alpha$ .

1  
2  
3  
4

The results of the phenotypic studied are summarized in the following Table:

Donor 1	HLA-DR	CD83	CD54	CD40	CD86	CD80
TNF- $\alpha$ (200 U/ml)	92.12% 877.54	70.02% 65.55	87.12% 137.49	83.44% 289.54	94.44% 180.81	0.49% 95.04
LCOS 1013 (5 $\mu$ g/ml)	81.69% 545.30	76.35% 119.62	89.39% <b>229.59</b>	75.02% <b>454.18</b>	93.33% 197	3.26% 90.79
LCOS 1013 (10 $\mu$ g/ml)	87.17% 500.55	68.20% 93.85	90.66% <b>229.17</b>	79.99% <b>411.53</b>	94.47% 184.14	2.92% 91.01
LCOS 1013 (25 $\mu$ g/ml)	94.52% 504.84	66.35% 105.29	93.15% <b>237.68</b>	91.22% <b>394.41</b>	91.07% 191.62	1.07% 99.64

5

**Table No.13**

6  
7

8 The functionality of the cells obtained was studied by means of mixed allogenic and  
9 autologous lymphocytic reactions, the results of which are presented in Figure 8.

10

11 The dendritic cells cultivated in the presence of LCOS 1013, at the three  
12 concentrations tested, exhibit a high allostimulatory capacity, comparable to that of  
13 the cells generated in the presence of TNF- $\alpha$ .

14

15 There again and irrespective of the concentration of LCOS 1013 used, it is observed  
16 that the dendritic cells cultivated in the presence of LCOS 1013 exhibit a capacity to  
17 stimulate autologous T lymphocytes much greater than the cells generated in the  
18 presence of TNF- $\alpha$ .

19

20

21

22

23

24

25

26

27

28